Ushering in 2019: Medtech’s Year to Come

Posted by Tobi Laczkowski on January 17, 2019

A new year has come, so it’s time to take a step back and make some observations about the industry’s 2018 evolution and provide some thoughts on how 2019 is shaping up.


>
Read More

A View From the Other Side: Four Lessons for Medtech Startups From OutcomeMD

Posted by Tobi Laczkowski on May 23, 2018

Maurice Solomon co-wrote this blog post with Tobi Laczkowski.

We recently published a Q&A with Tim Schmid, the chief strategic customer officer at the Johnson & Johnson Medical Devices Companies. He provided an excellent overview of the changing healthcare market, and how J&J and other large medtech companies are pivoting along with it. 


>
Read More

Threading the Needle: Post-Merger Communication and Compensation Plans

Posted by Tobi Laczkowski on November 29, 2017

For many medtech companies, the end of the calendar year is also the end of the fiscal year—a critical period of transition as management teams prepare organizational design strategies for the following year. Organizations in the midst of integration mergers and other transitions can expect even bigger changes during this time than in “normal” years. They need to thread the needle between over-communicating and under-communicating during this period of uncertainty while balancing the inherent challenges of creating a combined organization with unified values, processes and goals. With that in mind, management teams face a fundamental dilemma: How best to communicate what sales teams can expect in the next year without disrupting necessary end-of-year activities.


>
Read More

Here Come the Patients: The Increasing Role of Patient Preferences in FDA Decision-Making

Posted by Tobi Laczkowski on April 12, 2017


Patient empowerment is manifesting itself in many forms across the healthcare landscape, and its influence on medtech approvals is growing.


>
Read More

The State of Major CMS Health Initiatives: Winners, Losers and the Impact of the Trump Administration

Posted by Tobi Laczkowski on December 14, 2016


If we thought that change was accelerating in the last couple of years, we may be in for a “You ain’t seen nothing yet” moment. In the past several days, President-elect Trump nominated personnel to lead the Department of Health and Human Services (Rep. Tom Price, a Republican from Georgia) and CMS (Seema Verma, a health policy consultant). Not surprisingly, both are allies, and have their eyes on “repealing and replacing” the Affordable Care Act. Repealing is the easy part, but replacing it will be much more difficult. The two of them have actively spoken out against value-based payment programs, including the bundled payment initiatives, and Price previously has introduced legislation specifically to dismantle those programs. He also has criticized the Comprehensive Care for Joint Replacement (CJR) program, saying that CMS has overstepped its authority in rolling it out. 


>
Read More